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UV spectrophotometry is an analytical technique used routinely for qualitative and quantitative assay due the low cost and 
reliability during analysis. In this work, it was validated a quantitative UV method for determination of agomelatine in 
coated tablets. The parameters specificity, linearity, precision, accuracy and robustness were evaluated according to official 
guidelines. Methanol was selected as solvent and the maximum wavelength for drug analysis was 230 nm. The purposed 
assay showed to be specific and the linearity was proved in a range of 0.5 - 2.5 µg/mL. The RSD values obtained during 
precision assay (inter-day RSD = 1.75%) indicated the method reproducibility, and the accuracy testing showed good 
results from recovery test. Robustness assay was complementary and showed that the purposed method is adequate for 
drug quantitation in commercial samples, being a reliable alternative to chromatographic assay. 
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Introduction 
 
Agomelatine is the first non-
monoaminergic antidepressant drug approved 
for the treatment of major depressive disorder.  
This new drug acts as agonist of melatonergic 
MT1/MT2 receptors as well as an antagonist of 
serotonergic 5-HT2C receptors, resulting in an 
increased extracellular release of noradrenaline 
and dopamine in the frontal cortex. This unique 
mechanism of action confers to agomelatine the 
ability to regulate circadian rhythms (1-3). 
Clinical efficacy studies have shown that 
agomelatine has similar action to other 
antidepressant drugs, such as venlafaxine, 
paroxetine and sertraline (4-6). 
Chemically analogous to melatonin, 
agomelatine ((N-[2-(7-methoxy-1-
naphthyl)ethyl]acetamide) (Figure 1) is 
characterized as a white crystalline powder, 
being practically insoluble in water and very 
soluble in organic solvents such as ethanol, 
methanol and dichloromethane (3,7). 
Developed by the Servier Laboratories Ltd 
(Neuilly, France) industry, agomelatine was 
approved for clinical use in Brazil since 2009 
and is marketed as coated tablets (Valdoxan® 
25 mg) (8). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Chemical structure of agomelatine. 
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The scientific literature reports some 
analytical assays applied to agomelatine in 
different matrices. Among them, we 
highlighted chromatographic methods for its 
determination in biological fluids (9), analysis 
of related impurities (10), and method for 
quantitation in pharmaceuticals (11). Being an 
alternative to chromatographic assay, in the 
present study we aimed to develop an UV 
spectrophotometric method for quantitative 
analysis of agomelatine in commercial sample, 
applying validation protocols.  
 
Experimental 
 
Chemicals and apparatus  
 
Agomelatine reference standard (99.91 %) 
was purchased from BOC Sciences (CA, USA). 
Valdoxan® (Servier Laboratories Ltd.) 
containing 25 mg of agomelatine were 
purchased in the local market. The excipients 
used for the placebo solution (lactose 
monohydrate, starch, povidone, sodium starch 
glycolate, stearic acid, magnesium stearate, 
anhydrous colloidal silica, hypromellose, 
yellow iron oxide, glycerol, macrogol,  
magnesium stearate, titanium dioxide) were 
acquired from different suppliers. Methanol 
and acetonitrile UV-HPLC grade were 
purchased from Merck (Darmstadt, Germany). 
The UV spectrophotometric method was 
performed on an UV-1800 UV/Vis 
Spectrophotometer Shimadzu (Kyoto, Japan) 
using 1 cm quartz cells. For the analysis, the 
wavelength was set at 230 nm and the results 
were processed in UVProbe software. 
 
Standard and sample preparation 
 
A stock solution of agomelatine standard 
reference 100 µg/mL was prepared. For it, 5 mg 
of agomelatine were weighted and transferred 
to 50 mL volumetric flask, being solubilized in 
methanol. From this solution, different 
concentrations of analytical solutions were 
obtained by successive dilutions. 
For sample solutions, twenty tablets were 
weighed and crushed to a fine powder. An 
accurately weighed amount of tablet powder 
equivalent to 10 mg of agomelatine was 
transferred to a 100 mL volumetric flask with 
70 mL of methanol and sonicated for 45 min, 
followed by adding the same solvent to make 
up the volume. After sonication, the solutions 
were filtered on quantitative filter paper and 
diluted at the working concentrations, using the 
same solvent.  
 
Validation  
 
The UV-spectrophotometry method was 
validated according to official validation 
guidelines (12,13). The parameters studied 
were specificity, linearity, precision, accuracy 
and robustness.  
 
Specificity   
 
The specificity was assessed by testing 
analytical interferences from excipients. This 
analytical parameter was determined by 
comparing ultraviolet absorption spectra 
obtained from agomelatine standard solution, 
sample solution and placebo. The spectra were 
obtained in the range of 200 to 400 nm, and the 
overlap of absorption bands was evaluated. 
Through spectral scans, it was also possible to 
determine the absorption wavelength maxima 
of agomelatine when solubilized in methanol. 
 
Linearity  
 
The method linearity was studied by 
performing three independent analytical curves, 
within five concentration levels ranging 0.5 - 
2.5 µg/mL. Standard plots (concentration 
versus absorbance) were constructed, and 
linearity was evaluated statistically by linear 
regression analysis through least square method 
and applying ANOVA (analysis of variance). 
 
Precision   
 
Precision was determined by repeatability 
(intraday) and intermediate precision 
(interday). Repeatability was evaluated by 
assaying six samples solutions at 2.0 µg/mL 
during the same day, and the intermediate 
precision was studied by comparing the assays 
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on three different days. The analyses were done 
in triplicate and results were expressed as the 
relative standard deviation (RSD) of the 
analytical measurements. Samples were 
prepared as previously described. 
 
Accuracy  
 
Accuracy was determined based on the 
recovery of known amounts of agomelatine 
reference standard added to samples at the 
levels of 5, 10 and 20% of the sample 
concentration (2.0 μg/mL).  The accuracy was 
calculated as the percentage of the drug 
recovered and also expressed as the relative 
standard deviation (RSD) between the 
measurements.  
 
Robustness 
 
Robustness was determined by through 
small modifications in the established 
analytical conditions. The experiments were 
conducted by testing two different 
manufacturers for the solvent (methanol): 
Merck (Darmstadt, Germany) and Vetec (São 
Paulo, Brazil); and also through small 
variations in the selected wavelength for 
analysis (228 nm and 232 nm).    
 
Results and Discussion 
 
UV-visible spectrophotometry is an 
analytical technique widely used in the quality 
control of drugs, being present in official 
monographs, for identification and quantitation 
(14). This technique is highlighted in the 
scientific literature, in which several reports are 
focused in drug quantitation with a 
performance equivalent to HPLC, i.e. assaying 
fluoxetine (15), sulfasalazine (16), paliperidone 
(17) and posaconazole (18). In these studies, 
there is no significant difference between the 
results obtained by both techniques. 
Although there are limitations regarding 
specificity, the UV-spectroscopy presents some 
advantages when compared to chromatographic 
methods, such as faster analysis, low operating 
costs and low generation of waste. An 
alternative for improve the specificity and 
sensitivity of the technique is to perform UV 
derivative spectrophotometric method (19). 
This method consists in calculating 
mathematically the derivative of the obtained 
spectra, improving resolution and reducing 
noise and matrix effects (19,20). These 
advantages are determinants for new analytical 
investigations with quantitative focus.     
In the present study, the method 
development started with preliminary tests, 
applied to establish better conditions for 
analyses, studying the solvents for sample 
extraction, the concentration for analyses and 
the ʎmax for quantification. In order to 
determine the best wavelength for analysis, 
scans were performed in the range of 200 to 400 
nm, whose results indicated the maximum 
absorbance at 230 nm. 
Due the low drug solubility in water and 
based on studies already published in the 
literature, we selected acetonitrile and methanol 
as solvents, evaluating the drug extraction in 
different times by ultrasonic bath. Samples 
submitted to the extraction with acetonitrile 
presented turbidity and resistance to filtration, 
and the results illustrated a higher variation in 
the drug content after extraction. Using 
methanol, the extraction profile is presented in 
Table 1. 
 
Table 1 Agomelatine content (%) after extraction from coated tablets by using 
ultrasonic bath, methanol, and after different times.  
 
Time (min) Amount (%) 
Mean amount 
(%) 
RSD 
15 
96.87 
95,40 1.92 93.34 
96.00 
30 
95.81 
98,45 2.33 99.62 
99.93 
 102.00 
101,88 0.16 45 101.75 
 101.90 
 
Representative UV spectra of agomelatine 
standard reference, sample solution and 
placebo are presented in Figure 2, at the 
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wavelength selected for analysis (230 nm), it is 
possible to observe a small absorbance from 
placebo solution, less than 2% of the maximum 
absorbance from agomelatine reference 
standard. Experimentally, this performance 
indicates that there is no interference in the 
analysis. The method is specific for the 
intended analysis. 
 
 
 
 
 
 
 
 
Linearity was evaluated in the concentration  
 
Figure 2 UV spectrum of agomelatine reference substance (A), sample solution 
(B) and placebo solution (C), prepared in methanol at a final concentration of 2.0 
μg/mL.  
 
range of 0.5 to 2.5 μg/mL. The regression 
equation obtained was y = 0.3225x - 0.0044 and 
the correlation coefficient was r=0.9998. 
Statistical analysis by ANOVA confirmed the 
linear regression (Fcalculated = 4777 > Fcritical = 
4.96; p = 0.05) and shows that there is no 
deviation from linearity (Fcalculated = 2.0 < Fcritical 
= 3.71; p = 0.05). For the intercept, the 
statistical p‐value obtained (0.179) indicated 
that there is no statistical difference from zero 
point in the calibration range worked at the 95% 
confidence level. The residual plots 
demonstrated the absence of outliers, and the 
Cochran C-test indicated homoscedasticity of 
residuals variance (Ccalculated = 0.570 < Ccritical = 
0.684). The results obtained from linearity 
parameter study are summarized in Table 2. 
 
Table 2. Linearity results obtained from validation of UV spectrophotometric 
method for quantitative determination of agomelatine in coated tablets. 
 
Parameter  Results 
Calibration range  0.5 – 2.5 µg/mL 
Regression equation  y = 0.3225x – 0.0044 
Slope ± standard deviation 0.3225 ± 0.0070 
Intercept ± standard deviation 0.0044 ± 0.0037 
Correlation coefficient (r) 0.9998 
As illustrated in Table 3, the quantitative 
values obtained from precision study showed 
repeatability (intraday assay) with low values 
of RSD, ranging between 0.58 to 2.66. The 
intermediate precision was determined by 
performance of sequential analysis on three 
different days. These results were confirmatory 
for the expected reproducibility in this 
experimental purpose. Accuracy was studied by 
applying the recovery test, which was 
performed by adding the reference standard to 
the sample solution and analyzing the total drug 
content in the final matrix, expressing the 
results as percentage of drug recovered. As 
described in Table 4, the proposed method by 
UV spectrophotometry showed to be accurate 
for agomelatine determination, presenting an 
average recovery between 99.11% and 
103.97%, being considered satisfactory. The 
method was also shown to be robust, 
considering the experimental modifications 
made in order to evaluate this parameter. 
Testing different wavelengths of analysis and 
different manufacturers for the solvent, the drug 
content was not influenced, demonstrating that 
the method support little variations during 
analysis.    
 
Table 3 Results obtained for repeatability and intermediate precision parameters, 
studied during validation of UV method for quantitation of agomelatine in coated 
tablets. 
 
 
Repeatabilitya 
Intermedia
teb 
RSD 
Day 1 Day 2 Day 3 
Amount 
% 
105.64 104.28 106.22 
104.68 1.75 
104.73 104.67 106.87 
104.73 103.43 108.10 
102.92 103.37 108.55 
104.67 103.31 101.75 
105.12 103.24 102.77 
Mean 104.63 103.71 105.71   
RSD 0.87 0.58 2.66   
a mean of  three determinations. 
b mean of the determinations obtained in three days of analysis. 
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Table 4 Results obtained from recovery testing studied for validation of UV 
method for quantitation of agomelatine in coated tablets. 
 
 
Concentration (µg/mL) 
Concentration  
added 
(µg/mL) 
Concentration  
found 
(µg/mL) 
Recoverya 
(%) 
RSD 
Level 1 0.10 
0.104 
103.97 0.79 0.102 
0.104 
Level  2 0.20 
0.197 
99.11 0.38 0.199 
0.197 
Level  3 0.40 
0.411 
102.06 0,89 0.401 
0.402 
a mean of three determinations. 
 
Conclusions 
 
A simple, fast and reliable UV 
spectrophotometric method for quantitative 
analysis of agomelatine in coated tablets was 
developed and validated. The proposed method 
presented adequate performance for the 
intended analysis, demonstrating to be 
sensitive, precise and accurate. In addition, this 
UV method represents a real alternative to 
chromatographic assay, considering the routine 
of quality control laboratories and more simple 
protocols focused on drug content 
determination batch to batch.  
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